Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
about
Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironmentCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.Integrin-linked kinase modulates lipopolysaccharide- and Helicobacter pylori-induced nuclear factor κB-activated tumor necrosis factor-α production via regulation of p65 serine 536 phosphorylation.Protein engineering of the N-terminus of NEMO: structure stabilization and rescue of IKKβ binding.The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells.Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomasCurcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathwayThe NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Cleome rutidosperma and Euphorbia thymifolia Suppress Inflammatory Response via Upregulation of Phase II Enzymes and Modulation of NF-κB and JNK Activation in LPS-Stimulated BV2 Microglia.Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer.Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.Combination Therapies Targeting HDAC and IKK in Solid Tumors.
P2860
Q27025321-36E146CD-1A9F-474A-BDC8-F66340B0547AQ28540339-2887F3B7-3EEA-43EE-B771-9814D6F86A2EQ33983255-E2081CC9-0577-4215-9164-047122656040Q34256144-28EBDED9-DCA2-4D64-9B5B-B5D5AE79B67EQ34283506-AEF31B9F-C2EF-4AE4-B01F-2D985864DB34Q34463911-903B3ECB-D5F8-4CB5-B8C5-0CE6EA1E85E9Q34662493-3CCB4C72-F4D1-4E71-B08C-1624B4CEA346Q35898212-D238905A-7A64-4183-9F46-F8216A5E588FQ35977804-816E61C5-F7D0-466A-9394-6DEA88C1EC73Q36412841-B75180B4-B70C-4D22-8FE0-363271B128C4Q36876973-C089B464-8D19-4E82-86AD-E6052ACB0988Q37286324-E1E0323E-68E9-4153-A79C-46F06B1A0116Q37995693-1133A979-584B-4AE4-8ADA-19049F5ABA4DQ38975491-4F0A82F6-BCAF-4496-ABAD-B8EC0C6BED08Q49887757-9BB61592-2527-4A5F-A9FD-CEC8F06FE885
P2860
Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@ast
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@en
type
label
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@ast
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@en
prefLabel
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@ast
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@en
P2093
P2860
P356
P1476
Disruption of IkappaB kinase ( ...... deacetylase (HDAC) inhibitors.
@en
P2093
Lora B Kramer
Shuang Chen
Steven Grant
Vanessa L Funk
Xin-Yan Pei
P2860
P304
34036-34050
P356
10.1074/JBC.M111.284216
P407
P50
P577
2011-08-04T00:00:00Z